linjc16/ctgov huggingface dataset:
Tri-modal Imaging Instrument for Thyroid Cancer

Study Overview
=================
Brief Summary
-----------------
Thyroid cancer affects 6,000 Canadians each year. Nodules on the thyroid are detected using ultrasound imaging and surgery is the most common treatment. However, most nodules are benign, and therefore a biopsy is needed to decide whether surgery is necessary. Ultrasound imaging is very sensitive for localizing nodules, but does not differentiate between cancerous and benign ones. To address this limitation of US imaging, investigators have designed and constructed, in collaboration with Sogang University, Seoul, S. Korea, a novel imaging system that performs complimentary imaging modalities (ultrasound (US), photoacoustic (PA)) that could potentially help diagnose nodules without the need for biopsy and unnecessary surgery.

Official Title
-----------------
Clinical Evaluation of a Prototype Tri-modal Imaging Instrument for Thyroid Cancer

Conditions
-----------------
Thyroid Neoplasms, Thyroid Cancer, Thyroid Nodule

Intervention / Treatment
-----------------
* Device: Tri-modal imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients with thyroid nodules (cancerous, benign or undetermined) 18 years of age or older Have been consented to their standard-of-care surgery for resection of the thyroid (partial or complete) and lymph nodes (if applicable) Have had pre-surgical US imaging of the thyroid and lymph nodes Exclusion Criteria: Inability to provide informed consent Pre-operative therapy for current thyroid cancer (including chemotherapy, endocrine therapy and radiotherapy) History of photosensitivity or skin disease (exposure to laser light is involved in PA imaging) Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tri-modal imaging<br>Ultrasound and photoacoustic imaging of thyroid and adjacent lymph nodes. Imaging time: Approximately 30 minutes | Device: Tri-modal imaging<br>* This trimodal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detect/localize thyroid nodules and lymph nodes in vivo by using tri-modal imaging |  | up to 5 months |
A Randomized Controlled Trial on the Effect of Exercise on Physical, Cognitive and Affective Function in Dementia Subjects

Study Overview
=================
Brief Summary
-----------------
Studies have shown conflicting results of the effect of exercise on dementia patients. The aim of this study is to examine the role of physical activity on the risk of cognitive impairment and dementia in older persons. To promote the benefits of aerobic exercise on dementia patients and encourage exercise prescription in the management of dementia subjects.

Official Title
-----------------
To Study the Effect of Exercise Training in Term of Aerobic Exercise for 3 Months, on the Physical, Cognitive and Affective Function in Dementia Subjects

Conditions
-----------------
Dementia

Intervention / Treatment
-----------------
* Procedure: Aerobic exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: MMSE<26 Age >60 Community dwelling and ambulatory Have a caregiver that is willing to participate and escort patient to hospital for training and assessment Exclusion Criteria: MMSE<10 live in old age home poor mobility, unable to attend exercise training no carer to bring patient to attend hospital training

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Aerobic exercise training|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physical function measurement using SF-12 |  | every 3 months for 1 year | 
| Affective function measurement by Cornell depression score |  | every 3 months for 1 year | 
| Cognitive function by MMSE and ADAS-cog |  | every 3 months for 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6 minutes walk, functional reach, Berg balance scale |  | every 3 months for 1 year | 
| Carer stress scale |  | every 3 months for 1 year | 
| No. of fall/restricted activity days/time spend in exercise or walking |  | every 3 months for 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dementia
German Chest Pain Unit (CPU)-Register

Study Overview
=================
Brief Summary
-----------------
The Chest Pain Unit (CPU) register is a nationwide scientific investigation, in which data concerning the hospital-stay within the Chest Pain Unit are documented. Furthermore, a Follow-up via telephone is conducted after 3 months.

Detailed Description
-----------------
The aim of a Chest Pain Unit (CPU) is to clarify unclear chest pain quickly and specifically. Present data from Germany, the USA and England prove that the organisation models of a CPU lead beside a drastic reduction of mortality also to a cost reduction as well as a shortening of the average inpatient hospital stays. Therefore it seems reasonable to assign a minimum standard to CPUs. Although there are internationally already standards for CPUs up to complete certification programmes, it is an explicit wish of the German society for cardiology (DGK) to create an own standard which considers on the national circumstances. The aim of the CPU register is the internal and external validation of the care quality of CPU including Benchmark reports and risk-adjusted comparisons.

Official Title
-----------------
Deutsches CPU-Register. Unterstützt Durch Die Deutsche Gesellschaft für Kardiologie.

Conditions
-----------------
Chest Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients that are admitted to a Chest Pain Unit are included in this register. Exclusion Criteria: Missing informed consent (informed consent can NOT be given in the acute phase of the disease, if consciousness is limited at that time; instead the patient will be asked for his consent at a later point of time, when he is fully conscious).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Internal and external validation of the medical care quality in the field of Chest Pain Units | including benchmark reports and risk adjusted comparisons. | hospital stay | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Documentation of CPU complications | including mortality, serious but non-fatal complications (e.g. stroke, heavy and moderate bleedings) as well as documentation of the medication at hospital discharge | up to 30 hours on average | 
| Documentation of long-term mortality and serious but non-fatal complications | as well as additional hospital admissions and medication | 3 months after discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chest Pain Unit, Myocardial infarction, Register, Admission to a Chest Pain Unit for any reason
Evaluation of Biomarkers of Traumatic Brain Injury

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to evaluate the utility of the Banyan UCH-L1/GFAP Detection Assay as an aid in the evaluation of suspected traumatic brain injury (Glasgow Coma Scale score 9-15) in conjunction with other clinical information within 12 hours of injury to assist in determining the need for a CT scan of the head.

Official Title
-----------------
A Prospective Clinical Evaluation of Biomarkers of Traumatic Brain Injury

Conditions
-----------------
Traumatic Brain Injury

Intervention / Treatment
-----------------
* Other: Head CT scan and blood draw within 12 hours of injury


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subject is at least 18 years of age at screening suspected traumatically induced head injury as a result of insult to the head from external force GCS 9-15 at time of informed consent workup includes head CT scan as part of clinical emergency care within 3 hours of presenting and within 12 hours of injury blood sample collected within 3 hours of presenting and within 12 hours of injury subject or legal representative is willing to undergo informed consent Exclusion Criteria: participating in an interventional, therapeutic clinical study that may affect the results of this study (an observational study acceptable) time of injury cannot be determined primary diagnosis of ischemic or hemorrhagic stroke venipuncture not feasible a condition precluding entry into the CT scanner subject has a neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, brain tumors, and history of neurosurgery, stroke or TIA within the last 30 days administration of blood transfusion after head injury and prior to study blood draw subject is otherwise determined by the Investigator to be unsuitable for participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Suspected traumatic brain injury with head CT<br> | Other: Head CT scan and blood draw within 12 hours of injury<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of assay result with absence of acute intracranial lesions |  | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Traumatic Brain Injury, Head Injury
Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia

Study Overview
=================
Brief Summary
-----------------
50 pregnant females were divided in two groups, twenty five as a control group and twenty five as high risk group; they were subjected to uterine artery Doppler, measurement of maternal serum and detection of (MTHFR) gene polymorphisms in first trimester at 11 to 14 weeks of gestation, all pregnancies were followed until 40 weeks for development of pre-eclampsia

Detailed Description
-----------------
50 pregnant females were divided in two groups, twenty five as a control group and twenty five as high risk group; they were subjected to uterine artery Doppler, measurement of maternal serum (pp-13) and detection of (MTHFR) gene polymorphisms in first trimester at 11 to 14 weeks of gestation, all pregnancies were followed until 40 weeks for development of pre-eclampsia

Official Title
-----------------
Maternal Serum Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia and Relation to Maternal and Neonatal Outcome

Conditions
-----------------
Preeclampsia

Intervention / Treatment
-----------------
* Other: ultrasound monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women at 11 to 14 weeks of gestation Exclusion Criteria: fetal anomalies other medical diseases as diabetes mellitus, renal or liver diseases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| preeclmapsia<br>women developed preeclampsia. ultrasound monitoring and uterine artery Doppler | Other: ultrasound monitoring<br>* Uterine artery Doppler assessment<br>|
| control<br>women with normal blood pressure all through pregnancy. ultrasound monitoring and uterine artery Doppler | Other: ultrasound monitoring<br>* Uterine artery Doppler assessment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development of preeclampsia |  | 40 weeks pregnancy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preeclampsia, placental protein 13, Uterine artery doppler
Efficacy and Safety of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders.

Study Overview
=================
Brief Summary
-----------------
To assess the tolerability and effect of a probiotic product, when co-administered with antibiotics, on the incidence and duration of loose/watery stools following the antibiotic treatment in children.

Conditions
-----------------
Antibiotic-associated Loose/Watery Stools

Intervention / Treatment
-----------------
* Dietary Supplement: Probiotic capsules
* Dietary Supplement: Placebo capsules


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Children at the age of 1-11 years that have been ordinated to start antibiotic treatment except for penicillin. Possibility to initiate the probiotic treatment within 24 hours after the first dose of the antibiotic treatment. Children whose parents or legal caregivers have signed the informed consent to participate in the study. Exclusion criteria Chronic intestinal disease. Current immunodeficiency or immunosuppressive treatment. Chronic or acute diarrhoeal disease. Use of laxatives the week before inclusion in the study. Antibiotic treatment for the last four weeks before inclusion in the study. Known hypersensitivity to any of the ingredients in the probiotic product or the placebo [potato starch, silicon dioxide, capsule (hypromellose, water) ± bacterial culture]. Intake of any probiotic products for the last two weeks before inclusion in the study. Patient requiring hospitalisation. Lack of parents´/legal guardians´ informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Probiotics<br> | Dietary Supplement: Probiotic capsules<br> <br> |
| Placebo Comparator: Placebo<br> | Dietary Supplement: Placebo capsules<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of the incidence of loose/watery stools following antibiotic treatment in children. |  | 19-24 days |
Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2

Study Overview
=================
Brief Summary
-----------------
We hypothesised that intravenous infusion of PGI2 induced headache or migraine and cranial vasodilatation in migraineurs.

Official Title
-----------------
Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2

Conditions
-----------------
Headache, Migraine, Vasodilatation

Intervention / Treatment
-----------------
* Drug: Prostacyclin, PGI2
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: migraine without aura and healthy apart from that age 18-55 years 50-100 kg Secure contraceptives Exclusion Criteria: Tension Type Headache more than 3 time a month Other primary headaches Medication prior to the study (closer than 4 times plasma halflife) Migraine or headache 5 days prior to study. Hypertension (systolic BP >150 mmHg and/or diastolic BP >100 mmHg). Hypotension (systolic BP <90 mmHg and/or diastolic BP <50 mmHg). Heart-vessel disease of any kind incl cerebrovascular disease. Anamnestic or clinical signs of psychiatric disease or abuse. Anamnestic or clinical signs of disease of any kind relevant for participation in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Active treatment | Drug: Prostacyclin, PGI2<br>* 10 ng/kg/min of epoprostenol (stable PGI2)<br>|
| Placebo Comparator: 2<br>Placebo | Drug: Placebo<br>* NaCL 0,9%<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Headache and accompanying symptoms. Blood flow velocity in the middle cerebral artery, diameter changes in superficial temporal artery and radial artery. |  | 14 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure, pulse |  | 100 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Headache, Migraine, Vasodilatation
A Cost Analysis of Interstim Therapy

Study Overview
=================
Brief Summary
-----------------
A study to examine the impact that Interstim Therapy for Urinary Control has on health care utilization and costs within a health care system and the satisfaction with treatment expressed by patients using this therapy.

Detailed Description
-----------------
A retrospective administrative data analysis combined with a prospective health related quality of life/satisfaction with treatment survey designed to examine the impact that Interstim Therapy for Urinary Control has had on health care utilization and costs for the Kaiser Permanente system and the satisfaction with treatment expressed by patients using this therapy.

Official Title
-----------------
Interstim Therapy Retrospective Cost Analysis and Quality of Life

Conditions
-----------------
Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency)

Intervention / Treatment
-----------------
* Device: Interstim therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients implanted with an Interstim Therapy for Urinary Control or undergoing test stimulation for potential placement of Interstim Therapy during the period of June 1, 2002 through June 30, 2004 and who are enrolled with Kaiser-Permanente of Southern California.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Interstim therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
The most common thorax Computed tomography (CT) findings are multifocal ground-glass opacities and peripheral consolidation in patients with COVID-19. Septal thickening, bronchiectasis, pleural thickening, and subpleural involvement may also be observed. Although these findings are not specific to COVID-19, the severity of pulmonary involvement is expected to be correlated with thorax CT findings.

Detailed Description
-----------------
Thorax computed tomography severity score defined by Yang et al. can be used to evaluate the severity of pulmonary involvement in COVID-19 patients. We aimed to investigate whether the initial thorax computed tomography severity score can predict mechanical ventilation requirement and mortality in COVID-19 patients.

Official Title
-----------------
Initial Thoracic CT Findings and Mechanical Ventilation Requirement in Patients Admitted to Intensive Care Unit With COVID-19

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Diagnostic Test: CT-Scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years COVID-19 confirmed by positive RT-PCR and/or antibody testing CT scan at intensive care unit admission Exclusion Criteria: Loss of CT data Chronic lung disease findings by CT that may lead to misinterpretation RT-PCR results unavailable or negative Terminal cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID-19 patients<br>Patient tested positive for COVID-19 who had a CT scan | Diagnostic Test: CT-Scan<br>* Chest CT scan on admission to the intensive care unit<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Invasive respiratory support in patients with COVID-19 | Whether Thorax CT findings predict invasive mechanical ventilation requirement of covid-19 patients | 120 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality in patients with COVID-19 | Whether Thorax CT findings predict mortality of covid-19 patients | 120 days |